2000-2004 - Presidential Scholarship, St. Mary's University, San Antonio, Texas
Society for Neuroscience (SFN) (2007-Present)
Center for Biomedical Neuroscience, UT Health San Antonio (2007-Present)
Student member of the San Antonio Chapter of the SFN (2007-2012)
Student member of the International Behavioral Neuroscience Society (IBNS)(2010)
The Martinez laboratory investigates novel targets in attenuating the unwanted side-effect in the treatment of Parkinson’s disease (PD) known as L-DOPA induced dyskinesia (LID). Using a validated rat model of Parkinson’s disease, we are able mimic symptoms similar to LID and test various pharmacological compounds on whether they are able to decrease LID without affecting the therapeutic benefits of L-DOPA. Targets of interest that we investigate in decreasing LID include the endocannabinoid and peroxisome proliferator-activated receptor systems. Using the same validated rat model of PD, we are also investigating the relationship between traumatic brain injury and the development/progression of PD.
Previous Research Funding
F31NS073411-03, NIH/NINDS, 01/2011-12/2013
Ruth L. Kirschestein National Research Service Award Individual Fellowship
Project Title: Validation of PPARgamma Agonists as Anti-Dyskinetic Drugs Role: PI Description: Despite L-DOPA initial beneficial effects in treating Parkinson’s disease, its prolonged use results in the development of abnormal involuntary movements known as dyskinesia. Recent evidence suggests that activation of the nuclear receptor, PPARgamma, ameliorates these unwanted side effects once they are fully established. This proposal investigated whether co-administration of L-DOPA and a PPARgamma agonist (rosiglitazone) prevents the development of dyskinesias in a rodent model of Parkinson’s disease.
Selected Publications and Presentations
Drug Discovery in South Texas: Tapping into the Natural World for Solutions. Symposium Chair. SACNAS National Conference, San Antonio, TX. October 13, 2018
Parkinson’s Disease and L-DOPA-Induced Dyskinesia. Trinity University Biology Department Seminar Series. Trinity University, San Antonio, TX. February 9, 2015.
Martinez AA, Pisanu A, Carta AR and Giuffrida A. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesia without affecting L-DOPA and dopamine bioavailability in 6-OHDA-treated rats. (Slide Presentation) Society for Neuroscience: 638.07, 2011.
Tackling the debilitating side effects of Parkinson’s Disease treatment: What can we learn from a rat model? The Jose Miguel Cimadevilla Memorial Seminar Series. Mary’s University, San Antonio, TX. October 29, 2010.
Giuffrida A and Martinez AA. The Endocannabinoid System and Parkinson’s Disease. In: The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. (E. Murillo-Rodriguez, ed). Elsevier, Pp 63-81 (2017).
Giuffrida A and Martinez AA. Cannabinoids and levodopa-induced dyskinesia. In: Levodopa-induced Dyskinesia in Parkinson’s Disease (S. Fox, J. Brotchie, eds.). Springer, Pp 245-264 (2014).
Martinez AA, Morgese MG, Pisanu A, Macheda T, Paquette MA, Seillier A, Cassano T, Carta AR and Giuffrida A. Activation of PPAR gamma receptors alleviates levodopa-induced dyskinesia in 6-OHDA-treated rats. Neurobiol Dis. 74(C):295-304 (2015). PMID: 2586547
Seillier A, Martinez AA and Giuffrida A. Social withdrawal in Schizophrenia: lack of endocannabinoid-induced CB1 stimulation. Neuropsychopharmacology 38(9):1816-1824 (2013). PMID: 23563893
Cheng B, Martinez AA, Morado J, Scofield V, Roberts JL and Maffi SK. Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway. Neurochem Int. 62(1):31-42 (2013). PMID: 23142153
Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP and Giuffrida A. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA versus 5HT1A receptors. Eur J Neurosci. 36:3224-3234. (2012). PMID: 22861201
Martinez A, Macheda T, Morgese MG, Trabace L and Giuffrida A. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res. 72:236-242. (2012). PMID: 2219246
Cheng B, Maffi SK, Martinez AA, Acosta YP, Morales LD and Roberts JL. Insulin-like growth factor-I mediates neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells. Mol Cell Neurosci. 2011;47:181-190. (2011). PMID: 21545837
Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong JR, Lutz B., Marsicano G, Roberts JL and Giuffrida A. WIN55,212, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the MPTP mouse model of Parkinson’s disease. Eur J Neurosci. 29:2177-2186. (2009). PMID: 19490092